Exosome therapy holds immense promise, particularly in areas such as regenerative medicine, oncology, and drug delivery. However, it remains in its infancy. Academic researchers aiming to bring their discoveries to the clinic must overcome critical translational hurdles, chief among them: quality control (QC) for regulatory readiness.

Why QC Is Essential for Academic Researchers Entering the Therapeutic Space

Today, exosome-based products are often offered through private clinics, typically marketed without regulatory approval. The U.S. FDA has issued warnings that no exosome therapy is currently approved, citing concerns over inconsistent manufacturing and a lack of quality standards.

Academic innovators must recognize that demonstrating therapeutic potential alone is insufficient. Commercializing exosomes-based products demands robust systems for consistency, safety, and compliance, and QC is the cornerstone of this transition.

Unique Challenges in Exosome Quality Control (QC)

Exosomes, a subtype of extracellular vesicles (EVs), are heterogeneous biological nanoparticles, secreted by cells and carrying molecular cargo such as proteins, lipids, and RNAs.

These features make them therapeutically powerful—but also difficult to standardize.

Key QC Challenges:

• Uncertain Mechanism of Action (MoA):
  One of the fundamental challenges lies in the limited understanding of how exosomes achieve their therapeutic effects. This lack of clarity hinders the development of robust potency assays and complicates the definition of clear release criteria during manufacturing.

• Biological Variability:
  The composition and activity of exosomes can vary considerably depending on factors such as the originating cell type, passage number, and specific culture conditions. These variables influence the content and functional properties of the vesicles, creating inconsistency across batches.

• Mechanistic Complexity:
  The therapeutic activity of exosomes is largely driven by their cargo, including proteins, RNAs, and lipids, whose identities, mechanisms, and functional contributions are still not fully elucidated. This complexity adds another layer of difficulty in designing effective quality control assays.
  
  In response, preservation techniques such as cryopreservation and lyophilization have been employed to safeguard the integrity and stability of exosomes during storage. However, post-thaw equivalence to the original product must still be verified through further testing.

• Identification of Active Components:
  For any exosome-based therapeutic, it is critical to identify, quantify, and characterize the specific molecules responsible for the intended pharmacological, immunological, or metabolic activity. These may include not only encapsulated drug substances but also structural features of the exosome itself, such as particle size, which can influence biodistribution and metabolism. Thus, understanding these active components is essential for establishing meaningful quality control strategies.

• Fragile Structure:
  Exosomes are sensitive to physical and chemical stress. Their structure and functionality can be compromised during key stages such as isolation, purification, or long-term storage. Liquid formulations tend to degrade rapidly, while even frozen or freeze-dried forms may not fully preserve biological activity upon thawing.

These challenges have necessitated the use of advanced stabilization technologies, yet comprehensive evaluation is still needed to confirm that exosomes retain their original characteristics after processing and storage.

Importance of Sterility Testing in Exosome Manufacturing

Sterility testing is a fundamental QC requirement and a cornerstone of ensuring the safety of any biologic or cell-derived therapeutic product, including exosome-based therapies. Regulatory agencies such as the US FDA, European Medicines Agency (EMA), and other global authorities mandate stringent sterility and biosafety testing before approving products for clinical use. This requirement spans the entire development lifecycle from early-phase investigational products to commercialized therapies.

Exosomes are typically harvested from conditioned media of cultured producer cells. Because the production environment involves prolonged in vitro culture, complex purification steps, and manipulation of biological fluids, there is an inherent risk of contamination by bacteria, fungi, mycoplasma, or adventitious viruses. These contaminants can be introduced during raw material sourcing, handling, processing, or packaging and may not be entirely removed by downstream purification processes such as ultracentrifugation, tangential flow filtration (TFF), or size-exclusion chromatography.

Therefore, sterility testing is not merely a regulatory checkbox; it is a critical safety gate to ensure that the final exosome drug product does not pose infectious risks to patients. Contaminants in injectable EV preparations could result in severe adverse reactions, including sepsis, fever, or immune responses, especially given their frequent intravenous route of administration.

These are standard for cell-based therapies and biologics and are expected to apply equally to EV-based therapeutics:

Academic researchers moving into translational development of exosome-based therapeutics often face a steep learning curve when it comes to regulatory-grade safety testing, especially around sterility and microbial safety. Unlike preclinical research where basic aseptic techniques may suffice, therapeutic development demands validated, regulatory-compliant sterility and biosafety protocols.

Below are key areas academic researchers should pay special attention to:

The vesicular nature of exosomes and their origin from living cells increase the complexity of sterility assurance. Unlike small molecules, EVs are sensitive to standard sterilization procedures (e.g., filtration through 0.22 µm filters may retain or damage EVs), which limits terminal sterilization options. This makes aseptic processing and in-process microbial control even more critical.

Mycoplasma contamination is common in academic labs and may go unnoticed due to its small size and lack of turbidity in culture.

Routine mycoplasma testing (e.g., PCR-based or culture-based per EP 2.6.7) must be incorporated into the manufacturing and QC process.

For exosomes derived from immortalized or stem cell lines, ongoing mycoplasma surveillance of the cell bank and master working cell banks (MCB/WCB) is mandatory.

Sterility and related biosafety testing must be incorporated at both the drug substance (DS) and drug product (DP) stages. Early-phase products may be tested in batch mode (end-product testing), while later stages should implement real-time in-process controls to meet current Good Manufacturing Practice (cGMP) expectations.

For clinical trial timelines, rapid microbiological methods (RMMs), such as PCR-based or ATP bioluminescence assays, are gaining interest as acceptable alternatives to traditional 14-day sterility tests. These methods offer shorter turnaround while maintaining sensitivity, though their use must be validated and justified to regulators.

Viral safety evaluations should also consider the use of animal- or human-derived raw materials (e.g., serum, enzymes). Sourcing from certified suppliers and incorporating viral inactivation/removal steps (e.g., low pH treatment, nanofiltration) are part of a comprehensive viral clearance strategy.

Sterility results are often a prerequisite for product release. As exosomes are highly sensitive to processing and storage conditions, integrating QC checkpoints at harvest, formulation, and fill-finish steps helps ensure batch consistency and sterility.

USP <71> sterility tests must be validated for each product matrix, including exosome formulation buffers, which may interfere with microbial growth detection. Academic protocols may use culture-based sterility checks informally, but for therapeutic products, a validated sterility test must demonstrate detection of <10 CFU/mL of common contaminants under worst-case conditions.

If the formulation contains preservatives or antimicrobial excipients, their neutralization must be validated as part of the test.

Academic labs often use fetal bovine serum (FBS) or human serum, which are potential sources of adventitious viral contamination. Therapeutic-grade exosome production must use qualified, virus-screened, and traceable raw materials, or shift to serum-free or xeno-free culture systems.

Viral safety testing may involve:

• In vitro assays (e.g., CPE, hemadsorption)
• TEM for viral particle screening
• PCR panels for known viruses (e.g., CMV, HIV, parvovirus)
• Next-gen sequencing (NGS) for broader detection

In academia, exosome isolation often occurs in open systems (e.g., ultracentrifugation, manual pipetting), which are unsuitable for GMP production. Researchers should plan early for closed or functionally closed systems (e.g., TFF with sterile connectors) and aseptic processing under Grade A/B cleanroom conditions, as sterility cannot be achieved through terminal sterilization. It is advisable to engage with a GMP-experienced partner or CDMO early to map out a compliant aseptic manufacturing process.

Since aseptic conditions are critical, regular environmental and personnel monitoring during production is required to demonstrate continued control of the cleanroom environment.

In non-GMP academic settings, the working environment is rarely monitored for microbial burden.

When scaling toward therapeutic use, environmental monitoring (EM) plans should be implemented—monitoring air, surfaces, and personnel.

Documentation of cleanroom control and microbial recovery logs will be expected in regulatory filings.

In early-stage development of biologic products, a practical approach to quality control is often taken. Standard operating procedures are used to promote consistency across manufacturing runs. Batch-to-batch comparability is typically assessed by comparing newly produced exosomes against reference batches using a combination of biochemical, biophysical, and functional assays.

Transitioning from academic protocols to regulatory expectations often requires:

• Developing Standard Operating Procedures (SOPs) for all QC tests.
• Performing test method qualification and validation under ICH/USP guidelines.
• Establishing reference standards and specifications for release (e.g., sterility: no growth in 14 days, endotoxin: <5 EU/kg/hr).

The FDA requires that sterility and biosafety assessments for biologics follow guidelines such as the United States Pharmacopeia (USP) <71> for sterility testing, <85> for endotoxin testing, and ICH Q5A for viral safety evaluation. These standards are adapted and reinforced for Advanced Therapy Medicinal Products (ATMPs), including exosome therapeutics

Clarifying Exosome Identity: A Key Analytical Approaches for Academic Innovators

For academic innovators leading the development of exosome-based therapeutics, one of the most critical quality control challenges lies in accurately defining what has been isolated.

These nanoscale vesicles are a subtype of EVs and often share overlapping physical and biochemical features with other EV populations. This similarity makes it technically difficult to distinguish exosomes with certainty, yet such precise characterization is essential to ensure reproducibility and enable clinical translation.

Although proteomic analyses have identified a range of proteins frequently detected in exosome preparations, it is increasingly recognized that these markers are not exclusive to exosomes. Instead, they are more accurately described as “exosome-enriched” rather than “exosome-specific,” as various EV subtypes often carry overlapping molecular signatures.

To bring more clarity and standardization to the field, the International Society for Extracellular Vesicles (ISEV) has proposed minimal criteria for exosome identification. These include the detection of two key protein categories:

1. Transmembrane or GPI-anchored proteins associated with the plasma membrane or endosomal compartments, and
2. Cytosolic proteins with membrane-binding capabilities that are typically enriched in EVs.

When isolating exosomes from complex biological fluids such as serum, plasma, or urine, researchers must also evaluate sample purity. This involves checking for the presence of non-vesicular contaminants, such as albumin or apolipoproteins, which can co-purify with EVs and potentially skew downstream analyses or functional readouts.

For academic labs developing early-stage exosome technologies, establishing rigorous characterization protocols not only enhances the scientific robustness of their findings but also builds a foundation for future regulatory compliance and clinical scalability. A clear understanding of the strengths and limitations of available analytical tools—as outlined in the table below—is essential for designing quality control strategies that can withstand scrutiny from both peers and regulators.

Exosome Manufacturing Scale-Up and GMP Compliance

Manufacturing exosomes at clinical and commercial scales poses unique challenges:

• Isolation and purification: Must ensure reproducibility, purity, and potency. Ultracentrifugation is common in research settings but lacks scalability. SEC offers a more scalable alternative, and electroporation is often used for therapeutic cargo loading.
• Storage: Requires standardization of temperature, container type, and allowable shelf life. Product degradation can affect potency and safety.
• GMP facility: Clinical-grade production requires a technologically advanced, GMP-compliant facility. Quality management systems, validated processes, and release criteria are essential to meet regulatory expectations.

Understanding the mechanism of action (MoA) is essential for clinical translation. As with any biologic, regulators will require evidence of therapeutic effect, MoA, and batch-to-batch consistency. This includes:

• Clarifying active substances (e.g., RNAs or proteins carried by EVs)
• Developing functional potency assays
• Setting release specifications based on biological activity, not just physical characteristics

Conclusion: Clinical Translation of Exosomes Starts with Quality and Safety

Academic labs are driving innovation in exosome therapeutics—but without early attention to quality control, safety testing, dosing, and regulatory compliance, these innovations may fail to reach patients.

From preclinical studies through IND submission and GMP production, researchers must build clinically viable, scalable platforms. This means implementing robust analytical and safety testing methods, understanding dosing and biodistribution, and developing regulatory-grade data packages that support fast-track opportunities.

The path to clinical adoption is complex, but with the right frameworks, academic innovators can lead the charge in translating EV-based therapeutics into safe, effective, and approvable treatments.

References:

1. Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750
2. Ahn SH et al. Manufacturing Therapeutic Exosomes: from Bench to Industry. Mol Cells. 2022 May 31;45(5):284-290.
3. Cheng K and Kalluri R. Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics. Extracellular Vesicle, Volume 2, 2023,100029.
4. Wang CK, Tsai TH, Lee CH. Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes. Clin Transl Sci. 2024 Aug;17(8):e13904.